Communications regarding potential funding to Alzheimer Society Research Program for research to study the topic of Veterans and Dementia in a truly Canadian context.Read more
Ginette Petitpas Taylor · Minister of Veterans Affairs & M.P. for Moncton-Riverview-Dieppe, Veterans Affairs Canada (VAC)
Communications regarding potential funding to Alzheimer Society Research Program for research to study the topic of Veterans and Dementia in a truly Canadian context.Read more
Budget 2025 - as it relates to full and sustainable funding by the Government of Canada in: A Dementia Strategy for Canada: Together We Aspire
Mark Holland · Minister of Health, Health Canada (HC)
Create and fund programs to support Canadians diagnosed with young-onset dementia.Read more
Communications regarding potential funding to Alzheimer Society Research Program for research to study the topic of Veterans and Dementia in a truly Canadian context.
Funding opportunities under PHAC's Dementia Community Investment and Dementia Strategic Fund to support awareness-raising, dementia guidelines, diversity & Inclusion and best practices.
Budget 2025 - as it relates to full and sustainable funding by the Government of Canada in: A Dementia Strategy for Canada: Together We Aspire
Communications regarding the need for $20 million over 5 years through programs like Age Well at Home, and a longer-term and larger
commitment to programs like ASC's FirstLink® that have been proven to support people with dementia to live well as long as possible at home and in the community.
Health Canada as it pertains to the approval of disease-modifying treatments for Alzheimer's disease and other dementias that aim to slow or halt the progression of the disease.
Communications regarding the need to invest $15 million over 3 years to implement national standards for diagnosis, treatment and care for Alzheimer’s disease and dementia. This will ensure that the health systems across the country have access to quality standards to be able to realize the benefits of any disease modifying drugs approved in Canada.
Supriya Sharma · Chief Medical Officer, Health Canada (HC)
Health Canada as it pertains to the approval of disease-modifying treatments for Alzheimer's disease and other dementias that aim to slow or halt the progression of the disease.Read more
Budget 2024 - as it relates to full and sustainable funding by the Government of Canada in: A Dementia Strategy for Canada: Together We AspireRead more
Implementation metrics and success criteria for "A Dementia Strategy for Canada:Together We Aspire."
Create and fund programs to support Canadians diagnosed with young-onset dementia.
National standards and Safe Long-term Care Act include a common standard for the definition of an Essential Care Partner (ECP).
Create and fund programs to support Canadians diagnosed with young-onset dementia.Read more
Improve access to palliative and end-of-life care for people living with dementia in Canada.
Communications regarding the need to invest $15 million over 3 years to implement national standards for diagnosis, treatment and care for Alzheimer’s disease and dementia. This will ensure that the health systems across the country have access to quality standards to be able to realize the benefits of any disease modifying drugs approved in Canada.
Budget 2025 - as it relates to full and sustainable funding by the Government of Canada in: A Dementia Strategy for Canada: Together We Aspire
National standards and Safe Long-term Care Act include a common standard for the definition of an Essential Care Partner (ECP).
Communications regarding the need for $20 million over 5 years through programs like Age Well at Home, and a longer-term and larger
commitment to programs like ASC's FirstLink® that have been proven to support people with dementia to live well as long as possible at home and in the community.
Funding opportunities under PHAC's Dementia Community Investment and Dementia Strategic Fund to support awareness-raising, dementia guidelines, diversity & Inclusion and best practices.
Health Canada as it pertains to the approval of disease-modifying treatments for Alzheimer's disease and other dementias that aim to slow or halt the progression of the disease.
Implementation metrics and success criteria for "A Dementia Strategy for Canada:Together We Aspire."
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026.
Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month.
Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means.
Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence.
PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.